Denne situation påvirker naturligvis medicinalindustrien og myndighederne, men det er patienterne, der i første omgang berøres, for disse komplekse procedurer forhindrer dem i at drage fordel af bedre lægemidler.
Of course, this situation affects the pharmaceutical industry and authorities, but it is patients who are primarily affected because these complex procedures delay them receiving the benefits of improved medicines.